Literature DB >> 20980933

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines.

Nancy Bermal1, Leszek Szenborn, Alberto Edison, Marina Hernandez, Jerzy Pejcz, Ewa Majda-Stanislawska, Salvacion Gatchalian, Aurélie Fanic, Ilse Dieussaert, Lode Schuerman.   

Abstract

The safety and reactogenicity profiles of the 10-valent pneumococcal conjugate vaccine, PHiD-CV, and 7vCRM were comparable within the Philippines and Poland when coadministered as a booster dose with DTPw-HBV/Hib and poliovirus vaccines to toddlers primed with the same vaccines. Robust immune responses for all 10 vaccine pneumococcal serotypes and protein D following PHiD-CV booster vaccination were indicative of effective priming.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20980933     DOI： 10.1097/INF.0b013e3181f2da06

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  7 in total

1.  Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Authors:  Jan Poolman; Carl Frasch; Anu Nurkka; Helena Käyhty; Ralph Biemans; Lode Schuerman
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

Review 2.  10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

3.  Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.

Authors:  Tran Ngoc Huu; Nguyen Trong Toan; Ha Manh Tuan; Ho Lu Viet; Pham Le Thanh Binh; Ta-Wen Yu; Fakrudeen Shafi; Ahsan Habib; Dorota Borys
Journal:  BMC Infect Dis       Date:  2013-02-21       Impact factor: 3.090

4.  Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants.

Authors:  Brenda A Kwambana; Michael R Barer; Christian Bottomley; Richard A Adegbola; Martin Antonio
Journal:  BMC Infect Dis       Date:  2011-06-20       Impact factor: 3.090

5.  Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.

Authors:  Alassane Dicko; Gaoussou Santara; Almahamoudou Mahamar; Youssoufa Sidibe; Amadou Barry; Yahia Dicko; Aminata Diallo; Amagana Dolo; Ogobara Doumbo; Fakrudeen Shafi; Nancy François; Ana Strezova; Dorota Borys; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

6.  Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.

Authors:  Olumuyiwa O Odusanya; Yetunde A Kuyinu; Omolara A Kehinde; Fakrudeen Shafi; Nancy François; Juan Pablo Yarzabal; Kurt Dobbelaere; Jens U Rüggeberg; Dorota Borys; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2013-12-04       Impact factor: 3.452

7.  Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.

Authors:  Carla Magda Allan S Domingues; Jennifer R Verani; Ernesto Issac Montenegro Renoiner; Maria Cristina de Cunto Brandileone; Brendan Flannery; Lucia Helena de Oliveira; João Barberino Santos; José Cássio de Moraes
Journal:  Lancet Respir Med       Date:  2014-04-10       Impact factor: 30.700
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.